Orthopedic Devices Market Poised for 4.78% CAGR Growth Through 2030: FDA Approvals, Breakthrough Device Designation and AI-Enabled Devices Reshape the Market
DelveInsight's ' Orthopedic Devices - Global Market Insights, Competitive Landscape, and Market Forecast - 2030 ' report delivers a comprehensive analysis of the Orthopedic Devices market globally.
Key Takeaways
Market size projection: As per DelveInsight's analysis, the total market size of Orthopedic Devices globally is expected to surge from USD 44.09 billion in 2023 to USD 57.79 billion by 2030.
Patient population data: The report provides the total musculoskeletal disease potential pool, highlighting that 1.71 billion people suffer from conditions such as osteoarthritis, osteoporosis, and rheumatoid arthritis globally, with 528 million osteoarthritis and 18 million rheumatoid arthritis cases in 2019, plus ~300K people living with spinal cord injuries.
Key orthopedic device companies: Leading orthopedic device companies, such as Stryker Corporation, Zimmer Biomet, Johnson & Johnson, and Medtronic PLC
Pipeline assets: Some of the key orthopedic device innovations in the pipeline include the OSCAR PRO ultrasonic arthroplasty revision system, AccelStim Bone Growth Stimulator, AxSOS Ankle Fusion System, Insignia Hip stem, and AI-enabled UNID spinal fusion devices.
In August 2025, the FDA approved the SetPoint System, a neuroimmune modulation device for treating adults with moderately to severely active rheumatoid arthritis.
In June 2025, Maxx Orthopedics received FDA 510(k) clearance for their Freedom® Total Knee System Titanium Tibial Base Plate. This approval introduces a new material option, transitioning from CoCrMo to Wrought Titanium-6Aluminium-4Vanadium ELI Alloy (Ti6Al4V ELI) for the tibial base plate component.
In May 2025, Hyalex Orthopaedics secured FDA approval of its supplemental Investigational Device Exemption (IDE) application for the Freestyle Knee Implant.
In March 2025, Johnson & Johnson MedTech showcased major advances at the American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting. Building on their momentum from the previous year's 18 FDA 510(k) clearances and 45 global product launches, the company introduced cutting-edge implants, advanced techniques, and data-driven technologies across joint reconstruction, trauma, extremities, and spine specialties.
January 2025: OrthoPreserve received Breakthrough Device Designation and enrolled in the FDA TAP program for its Defender meniscus replacement implant.
Discover recent advancements in the Orthopedic Devices landscape @ Orthopedic Devices Recent Developments.
Orthopedic Devices Market Dynamics
The global orthopedic devices market reached USD 44.09 billion in 2023 and is expanding at a compound annual growth rate (CAGR) of 4.78%, projected to attain USD 57.79 billion by 2030. This growth reflects both demographic pressures, an aging population with 54.1 million U.S. residents aged 65 or older as of 2019, and the rising incidence of bone and joint disorders. Musculoskeletal conditions are the leading contributors to disability worldwide, driving substantial demand for implants, supports, and related devices.
Orthopedic devices market drivers include the increasing prevalence of osteoarthritis (528 million cases) and osteoporosis, occupational and non-occupational injuries, and technological innovation in implant materials and design. Innovations such as biocompatible titanium constructs and AI-integrated hardware are elevating clinical outcomes and reducing complication rates. For instance, ultrasonic arthroplasty tools like OSCAR PRO facilitate minimally invasive revisions, while AccelStim enhances fracture healing through targeted bone stimulation.
The advances in biomechanics, materials science, and regenerative engineering underpin device performance. Titanium interbody cages, porous polymer composites, and smart sensors are enabling load-sharing implants with real-time monitoring. Mechanistically, bone growth stimulators exploit electromagnetic or ultrasonic energy to upregulate osteoblast activity and accelerate fusion.
The orthopedic devices innovation and development is robust, with numerous devices in various trial phases. OrthoPreserve's Defender meniscus replacement is in breakthrough designation pathways, and Medtronic's UNID system illustrates the integration of AI in device-guided spinal fusion. Concurrently, Stryker and Zimmer Biomet are conducting post-market surveillance studies to refine long-term safety profiles.
The orthopedic devices competitive landscape features diversified strategies: major players invest in in-licensing and partnerships to expand portfolios, while mid-sized innovators focus on niche applications such as ankle and wrist arthrodesis. Strategic M&A activity is anticipated as companies seek to consolidate capabilities in biologics-enabled devices.
The orthopedic devices market barriers include regulatory hurdles for novel biomaterials, reimbursement constraints, and potential competition from non-implant therapies (e.g., biologics, cell therapy). However, opportunities abound in emerging markets, tele-enabled surgery, and personalized implant design via 3D printing. The future outlook projects continued growth driven by demographic trends, rising healthcare expenditure, and sustained R&D investment in next-generation orthopedic solutions.
Download the Orthopedic Devices Market report to understand which factors are driving the therapeutic market @ Orthopedic Devices Market Trends.
Orthopedic Devices Potential Patient Pool
Musculoskeletal disorders impact 1.71 billion individuals globally, with 528 million suffering from osteoarthritis and 18 million affected by rheumatoid arthritis as of 2019. Spinal cord injuries afflict approximately 296,000 patients worldwide, with 17,900 new cases annually. DelveInsight's epidemiology segmentation reveals that osteoarthritis accounts for the largest share of years lived with disability, followed by rheumatoid arthritis.
The total orthopedic devices eligible patient pools encompass those requiring surgical implants or supportive orthoses, with treated cases driven by healthcare access and device availability. Geographic analysis indicates North America leads market adoption, followed by Europe and Asia-Pacific, where aging demographics and expanding surgical capacity fuel device uptake. Forecasting through 2030 anticipates rising incident cases and an expanding treated cohort as minimally invasive and outpatient surgical centers proliferate.
Discover evolving trends in the Orthopedic Devices patient pool forecasts @ Orthopedic Devices Patient Pool Analysis.
Key Orthopedic Devices Companies and Competitive Landscape
The orthopedic devices sector is anchored by established players and dynamic innovators. Current treatment options range from prophylactic supports (braces, orthoses) to complex implants (total joint prostheses, spinal fusion systems).
Stryker Corporation leads with its Insignia Hip stem and AxSOS Ankle Fusion System, leveraging titanium design and updated screw arrays to improve fusion rates. Zimmer Biomet's portfolio includes knee and shoulder implants, while Johnson & Johnson focuses on advanced soft-tissue fixation devices. Medtronic's UNID rods and screws incorporate AI algorithms to optimize spinal alignment intraoperatively.
Orthopedic devices development activity features OrthoPreserve's Defender meniscus replacement entering pivotal trials under FDA Breakthrough Device designation and Orthofix's AccelStim in post-approval studies. Key partnerships include licensing agreements for biomaterial coatings and co-development of sensor-enabled implants. Market positioning emphasizes value-based outcomes, with companies forging payor contracts that reward reduced revision rates. Recent milestones encompass FDA clearances (AccelStim May 2022, UNID June 2021), AAOS product launches (Insignia March 2022), and strategic collaborations in 3D-printed implant manufacturing. Commercial arrangements involve joint ventures in emerging markets to enhance distribution networks. Collectively, these efforts define a competitive environment focused on enhancing patient outcomes, expanding indications, and driving long-term growth in the orthopedic devices landscape.
Delve deeper into the major and specialised companies in the Orthopedic Devices market @ Orthopedic Devices Competitive Landscape.
Conclusion
The orthopedic devices market is poised for sustained expansion through 2030, driven by demographic imperatives, technological innovation, and a diversified competitive field. Strategic collaborations, regulatory breakthroughs, and evolving clinical practices will shape the future, ensuring that next-generation implants and support devices meet the growing global demand for improved musculoskeletal health.
Table of Contents
1. Orthopedic Devices Market Report Introduction
2. Orthopedic Devices Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Orthopedic Devices Market Key Factors Analysis
6. Orthopedic Devices Market Porter's Five Forces Analysis
7. Orthopedic Devices Market Assessment
8. Orthopedic Devices Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us
About DelveInsight
DelveInsight is a leading business consulting and market research company focused on the healthcare and life sciences sectors, providing comprehensive market intelligence, competitive landscape analysis, and strategic insights to support decision-making across the pharmaceutical industry.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
8 minutes ago
- Globe and Mail
Patton Re-Launches Dante AV Encoders and Decoders with Colibri Codec at Slashed Pricing
Patton's new release of the FiberPlex FPX6000 DanteAV Audio/Video-over-IP Gateway features the lowest-ever market pricing, the Colibri Codec, and enhanced interoperability. FiberPlex™... Secure Digital Communications! GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Patton—world leader and of Unified Communications, ProAV, and media broadcast products—announces a fresh software release for the FiberPlex FPX6000 AVoIP Gateway series offered at half price. FiberPlex FPX60000 AVoIP Gateway Patton's AVoIP gateways are easy to install and use. The Dante controller makes routing, controlling, and monitoring audio/video traffic as simple as the push of a button. In August 2021, Patton was the first adopter and first to market with Dante AV products. Now, Patton is pleased to announce it has cut the pricing in half on its FPX6000 AVoIP Gateway—while adding software updates that support the latest Colibri firmware. Colibri is the newest video codec from Audinate developed specifically for AV-over-IP distribution. Colibri offers visually lossless quality and low subframe latency. The Patton FPX6000 now interoperates with every Dante AV Ultra product that supports the Colibri codec, including devices from Bolin, AJA Video, Adtechno, Yuan, Minnray, and PTZ Optics. Interop. The FPX6000 will also interoperate with Dante Audio from the Dante AV-A and Dante AV-H products. Later this year, a software update from Audinate for Dante AV-H will enable video transcoding between Dante AV Ultra and Dante AV-H. 4K. Dante AV technology integrates high-quality audio and 4K-video for transmission over 1-Gbps IP networks with practically zero latency. Patton's FPX6000 supports 4K60p 4:4:4. Easy. Patton's AVoIP gateways are easy to install and use. The Dante controller makes routing, controlling, and monitoring audio/video traffic and endpoints as simple as the push of a button. Patton's FPX6000 will also work with Dante Studio, Dante Domain Manager, and Dante Director. Channels. Patton FPX6000 gateways make it easy to insert 8 channels of audio (transmit or receive)—plus a video channel with HDCP encryption—into an existing Ethernet backbone. The Patton solution eliminates the performance issues and management difficulties formerly associated with Audio/Video-over-IP. Synchronized. By providing a single network clock for the entire system, Dante's audio and video synchronization eliminates alignment problems, reducing harmonic distortion and phase noise caused by jitter. Dante AV supports mixed audio-video-data networks while ensuring broadcast media has sufficient bandwidth—even on a standard enterprise gigabit Ethernet network. Connections. In addition to providing high-performance audio and video, the FPX6000 features a convenient, state-of-the-art set of peripheral connectivity options, including USB 2.0 and USB OTG for keyboard and mouse, infrared for remote controls—even serial signals for PTZ control. For more information about the FiberPlex FPX6000 DanteAV Audio/Video-over-IP gateway, go to In related news, Patton recently unveiled its second-generation, US-Made, commercial-grade, FIPS-140 ultra-secure SIP Phone with enhanced NG911 compliance. About Patton Patton is a world-renowned manufacturer of networking and communications technology, offering a wide range of solutions including VoIP, Ethernet extension, wireless, and fiber optic products. Founded in 1984 and headquartered in Gaithersburg, MD, Patton has a strong global presence and a reputation for delivering reliable and innovative solutions to a diverse customer base. Let's Connect!
Globe and Mail
8 minutes ago
- Globe and Mail
Barings Participation Investors Reports Preliminary Second Quarter 2025 Results and Announces Quarterly Cash Dividend Of $0.37 Per Share
The Board of Trustees of Barings Participation Investors (NYSE: MPV) (the "Trust") met on August 14, 2025, and would like to report its preliminary financial results for the second quarter of 2025. Financial Highlights (1) Three Months Ended June 30, 2025 Three Months Ended March 31, 2025 Total Amount Per Share (5) Total Amount Per Share (4) Net investment income (2) $ 3,396,864 $ 0.32 $ 3,351,767 $ 0.31 Net realized (losses) / gains (3) $883,063 $0.08 $(2,063,056) $(0.19) Net unrealized depreciation / appreciation $ (155,317) $ (0.01) $ 822,363 $ 0.08 Net increase in net assets resulting from operations $ 4,183,147 $ 0.39 $ 2,058,829 $ 0.19 Total net assets (equity) $168,117,718 $ 15.68 $167,580,570 $ 15.65 (1) All figures for 2025 are unaudited (2) June 30, 2025 figures net of less than $0.01 per share of taxes (3) June 30, 2025 figures net of less than $0.01 per share of taxes (4) Based on shares outstanding at the end of the period of 10,704,909 (5) Based on shares outstanding at the end of the period of 10,722,277 Key Highlights: Commenting on the quarter, Christina Emery, President, stated, "The Trust earned $0.32 per share of net investment income, net of taxes, for the second quarter of 2025, compared to $0.31 per share in the previous quarter The Trust has maintained its dividend this quarter, which is further confirmation of our credit philosophy, where we focus on leading businesses backed by strong sponsor ownership and conservative capital structures. This approach has historically generated stable returns and relative stability during economic stress. During the quarter, Barings continued to drive origination flow into quality, 1st lien senior secured middle-market investments as well as capitalizing on public fixed income investments where applicable. When constructing portfolios, we focus on investing in high-quality businesses that are leaders in their space and offer defensive characteristics that will allow them to perform through economic cycles.' The Board of Trustees declared a quarterly dividend of $0.37 per share, payable on September 12, 2025, to shareholders of record on August 29, 2025. During the three months ended June 30, 2025, the Trust reported total investment income of $4.5 million, net investment income of $3.4 million, or $0.32 per share, and a net increase in net assets resulting from operations of $4.2 million, or $0.39 per share. Net asset value ("NAV") per share as of June 30, 2025, was $15.68, as compared to $15.65 as of March 31, 2025. The increase in NAV per share was primarily attributable to net investment income of $0.32 per share, net realized gain on investments of $0.08 per share, partially offset by unrealized depreciation on investments of $0.01 per share and dividends and distributions of $0.37 per share. Recent Portfolio Activity During the three months ended June 30, 2025, the Trust made 15 new investments totaling $10.4 million and 40 add-on investments in existing portfolio companies totaling approximately $1.9 million. Liquidity and Capitalization As of June 30, 2025, the Trust had cash and short-term investments of $4.2 million and $24.8 million of borrowings outstanding. The Trust had unfunded commitments of $20.1 million as of June 30, 2025. Net Capital Gains The Trust realized net capital gains of $883,063 or $0.08 per share during the quarter ended June 30, 2025. By comparison, for the quarter ended March 31, 2025, the Trust realized net capital losses of $2,063,056 or $0.19 per share. About Barings Participation Investors Barings Participation Investors is a closed-end management investment company advised by Barings LLC. Its shares are traded on the New York Stock Exchange under the trading symbol ("MPV"). About Barings LLC Barings is a $456+ billion* global asset management firm that partners with institutional, insurance, and intermediary clients, and supports leading businesses with flexible financing solutions. The firm, a subsidiary of MassMutual, seeks to deliver excess returns by leveraging its global scale and capabilities across public and private markets in fixed income, real assets and capital solutions. Learn more at . *Assets under management as of June 30, 2025 Per share amounts are rounded to the nearest cent. PAST PERFORMANCE IS NOT NECESSARILY INDICATIVE OF FUTURE RESULTS Cautionary Notice: Certain statements contained in this press release may be "forward looking" statements. Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they are made and which reflect management's current estimates, projections, expectations or beliefs, and which are subject to risks and uncertainties that may cause actual results to differ materially. These statements are subject to change at any time based upon economic, market or other conditions and may not be relied upon as investment advice or an indication of the fund's trading intent. References to specific securities are not recommendations of such securities, and may not be representative of the fund's current or future investments. We undertake no obligation to publicly update forward looking statements, whether as a result of new information, future events, or otherwise. View source version on
Globe and Mail
8 minutes ago
- Globe and Mail
Average rate on a 30-year mortgage drops to lowest level since October
The average rate on a 30-year U.S. mortgage fell this week to its lowest level in nearly 10 months, giving prospective homebuyers a sorely needed boost in purchasing power that could help inject life into a stagnant housing market. The long-term rate fell to 6.58% from 6.63% last week, mortgage buyer Freddie Mac said Thursday. A year ago, the rate averaged 6.49%. Borrowing costs on 15-year fixed-rate mortgages, popular with homeowners refinancing their home loans, also fell. The average rate dropped to 5.71% from 5.75% last week. A year ago, it was 5.66%, Freddie Mac said. Elevated mortgage rates have helped keep the U.S. housing market in a sales slump since early 2022, when rates started to climb from the rock-bottom lows they reached during the pandemic. Home sales sank last year to their lowest level in nearly 30 years. This is the fourth week in a row that rates have come down. The latest average rate on a 30-year mortgage is now at its lowest level since Oct. 24, when it averaged 6.54%. Mortgage rates are influenced by several factors, from the Federal Reserve's interest rate policy decisions to bond market investors' expectations for the economy and inflation. The main barometer is the 10-year Treasury yield, which lenders use as a guide to pricing home loans. The yield was at 4.29% at midday Thursday, up slightly from 4.24% late Wednesday. The yield has come down the last couple of weeks after weaker-than-expected July U.S. job market data fueled speculation that the Fed will cut its main short-term interest rate next month. A Fed rate cut could give the job market and overall economy a boost, but it could also fuel inflation just as President Trump's tariff policies risk raising prices for U.S. consumers. Meanwhile, a new inflation report Thursday showed prices at the U.S. wholesale level jumped 3.3% last month from a year earlier. That's was well above the 2.5% rate that economists had forecast, and it could hint at higher inflation ahead. Earlier this week, the Labor Department said consumer prices rose 2.7% in July from a year earlier, unchanged from June. Higher inflation could push bond yields higher, driving mortgage rates upward in turn, even if the Fed cuts its key rate. Economists generally expect the average rate on a 30-year mortgage to remain above 6% this year. Recent forecasts by and Fannie Mae project the average rate will ease to around 6.4% by the end of this year. That may not be low enough to make a difference. While trends like declining home listing prices and more properties on the market in the Sunbelt and West now favor buyers, affordability remains a major hurdle for many aspiring homeowners. Home price growth has slowed nationally, but the median sales price of a previously occupied U.S. home still climbed to an all-time high of $435,300 in June. 'Homebuyers who have been relegated to the sidelines by high financing costs got some encouragement in the past two weeks, but it remains to be seen if it's enough to get more of them back in the game,' said Joel Berner, senior economist at The recent drop in mortgage rates has spurred many homeowners to refinance, however. Mortgage applications jumped 10.9% last week from the previous week as rates eased, boosted by homeowners seeking to refinance, according to the Mortgage Bankers Association. Home loan refinance applications made up nearly 47% of all mortgage applications. Refi loan applications jumped 23% from a week earlier -- the strongest showing since April. Meanwhile, applications for adjustable-rate mortgages, or ARMs, soared 25% to their highest level since 2022, MBA said. Many homeowners aren't waiting for rates to ease further before refinancing. Cash-out home refinancing activity surged to a nearly three-year high in the April-June quarter, as homeowners tapped some of the equity gains built up after years of soaring home prices.
